Michael Shea, MD
Cardiovascular Disease · Dover, DENPI 1659530178
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 399 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations.
Across 399 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$905
- Pfizer$850
- Amgen$712
- E.r. Squibb & Sons, L.L.C.$711
- AstraZeneca$477
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$454
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,339100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 79 | $905 |
| Pfizer | 48 | $850 |
| Amgen | 46 | $712 |
| E.r. Squibb & Sons, L.L.C. | 46 | $711 |
| AstraZeneca | 31 | $477 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 27 | $454 |
| Johnson & Johnson | 31 | $430 |
| Boehringer Ingelheim | 19 | $339 |
| Merck | 12 | $217 |
| Akcea Therapeutics, Inc. | 3 | $210 |
| Abbott | 11 | $194 |
| Boston Scientific | 3 | $77 |
| Bayer | 4 | $73 |
| Alnylam Pharmaceuticals Inc. | 3 | $66 |
| Medtronic(2 entities) | 3 | $58 |
| Esperion Therapeutics, Inc. | 3 | $56 |
| Regeneron Healthcare Solutions, Inc. | 3 | $52 |
| Novo Nordisk | 3 | $51 |
| Bridgebio Pharma, Inc. | 3 | $50 |
| Tactile Systems Technology Inc | 3 | $48 |
| Lundbeck LLC | 3 | $41 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Kestra Medical Technology Services, Inc. | 2 | $34 |
| Gilead | 1 | $31 |
| Bioventus LLC | 1 | $26 |
| Biotronik Inc. | 1 | $24 |
| Heartflow, Inc. | 1 | $21 |
| Irhythm Technologies, Inc. | 1 | $21 |
| BD | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Bardy Diagnostics, Inc. | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $14 |
| G Medical Diagnostic Services, Inc. | 1 | $13 |
| Daxor Corporation | 1 | $11 |
How this compares
$6,356 in reported general payments places this provider in the 70th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 346 | $425,361 |
| XareltoRivaroxaban | 150 | $186,498 |
| JardianceEmpagliflozin | 100 | $128,580 |
| MultaqDronedarone Hcl | 70 | $125,121 |
| EntrestoSacubitril/Valsartan | 75 | $122,295 |
| FarxigaDapagliflozin Propanediol | 67 | $94,860 |
| Repatha SureclickEvolocumab | 55 | $81,713 |
| BrilintaTicagrelor | 27 | $25,359 |
| Rosuvastatin Calcium | 833 | $21,329 |
| Ranolazine ErRanolazine | 114 | $11,718 |
| Ezetimibe | 275 | $11,199 |
| Atorvastatin Calcium | 688 | $10,544 |
| Metoprolol Succinate | 629 | $9,642 |
| Carvedilol ErCarvedilol Phosphate | 27 | $7,736 |
| Losartan Potassium | 346 | $5,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $850 | $425,361346 claims |
| Johnson & JohnsonXarelto | $430 | $186,498150 claims |
| Boehringer IngelheimJardiance | $339 | $128,580100 claims |
| Sanofi-aventis U.S. LLCMultaq | $18 | $125,12170 claims |
| NovartisEntresto | $905 | $122,29575 claims |
| AstraZenecaFarxiga, Brilinta | $477 | $120,21894 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Dover
- Eranga HaththotuwaDover$15K
- Gurmeet SinghDover$9K
- John ShuckDover$3K
- Khaled EljazzarDover$3K
- Jennifer EakinDover$2K
- Vinay HosmaneWilmington$256K
- Wasif QureshiBear$122K
- Rajinder PrasadLewes$72K
- Ehtasham QureshiLewes$52K
- Edward GoldenbergNewark$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.